{
    "2019-10-30": [
        [
            {
                "time": "",
                "original_text": "华熙生物IPO配售获机构热捧背后：业绩稳增长，迎玻尿酸红利",
                "features": {
                    "keywords": [
                        "华熙生物",
                        "IPO",
                        "配售",
                        "机构热捧",
                        "业绩稳增长",
                        "玻尿酸红利"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "港股退市两年后再登科创板，华熙生物(688363.SH)私有化背后的故事",
                "features": {
                    "keywords": [
                        "华熙生物",
                        "港股退市",
                        "科创板",
                        "私有化"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}